NCT07744893

Brief Summary

To evaluate whether adding conventional transcutaneous electrical nerve stimulation (TENS) to a standard conservative regimen (patient education, pharmacotherapy, and a home exercise programme) provides additional short- and medium-term benefit for pain, mandibular function, and quality of life in patients with temporomandibular disorders (TMD).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
13.2 years until next milestone

First Submitted

Initial submission to the registry

July 28, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 4, 2026

Completed
Last Updated

August 4, 2026

Status Verified

July 1, 2026

Enrollment Period

2.1 years

First QC Date

July 28, 2026

Last Update Submit

July 31, 2026

Conditions

Keywords

temporomandibular disorderstranscutaneous electric nerve stimulationorofacial painquality of lifephysical therapy modalities

Outcome Measures

Primary Outcomes (1)

  • Pain at rest assessed by Visual Analog Scale (VAS)

    Pain intensity at rest will be evaluated using a 10-cm Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores represent worse outcome/greater pain intensity.

    Baseline, week 2 (immediately post-treatment), and week 12 (3 months follow-up)

Secondary Outcomes (3)

  • Pain during jaw function assessed by Visual Analog Scale (VAS)

    Baseline, week 2 (immediately post-treatment), and week 12 (3 months follow-up)

  • Temporomandibular joint dysfunction assessed by the Modified Helkimo Clinical Dysfunction Index

    Baseline, week 2 (immediately post-treatment), and week 12 (3 months follow-up)

  • Mandibular range of motion measured in millimeters using a digital caliper

    Baseline, week 2 (immediately post-treatment), and week 12 (3 months follow-up)

Study Arms (2)

TENS Group

EXPERIMENTAL

Patients received conventional TENS (100 Hz, 200 µs, sensory-level, 30 min/session, 5 sessions/week for 2 weeks) in addition to a standard conservative regimen consisting of patient education, pharmacotherapy, and a home exercise programme

Device: Transcutaneous Electrical Nerve Stimulation (TENS)

Control Group

ACTIVE COMPARATOR

Patients received a standard conservative regimen alone, consisting of patient education, a two-week pharmacological course of dexketoprofen (50 mg/day) plus thiocolchicoside (16 mg/day), and a standardised home exercise programme. No TENS was applied.

Other: Standard Conservative Therapy

Interventions

Patient education about the resting position of the tongue and mandible and avoidance of parafunctional habits; a two-week pharmacological regimen of dexketoprofen 50 mg/day and thiocolchicoside 16 mg/day; and a standardised home exercise programme comprising active and passive jaw range-of-motion, isometric, and postural exercises

Also known as: Pharmacotherapy and Home Exercise Programme
Control Group

A charge-balanced biphasic waveform with a pulse width of 200 µs, a frequency of 100 Hz, and an amplitude adjusted to produce a comfortable, non-painful paraesthesia using an Intelect® TENS device. Sessions lasted 30 minutes and were applied 5 days per week for 2 weeks (10 sessions)

Also known as: Conventional TENS
TENS Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged between 18 and 65 years.
  • Patients diagnosed with temporomandibular disorders (TMD) according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) Axis I.
  • Patients who agreed to participate and signed the informed consent form.

You may not qualify if:

  • Facial pain attributable to another condition (sinusitis, migraine, tension-type headache, trigeminal neuralgia).
  • TMJ involvement secondary to an inflammatory systemic disease.
  • TMJ subluxation.
  • Degenerative cervical disease restricting neck movement.
  • Any contraindication to TENS.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Necmettin Erbakan University

Konya, Konya, 42090, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Temporomandibular Joint DisordersFacial Pain

Interventions

Drug TherapyTranscutaneous Electric Nerve Stimulation

Condition Hierarchy (Ancestors)

Craniomandibular DisordersMandibular DiseasesJaw DiseasesMusculoskeletal DiseasesJoint DiseasesMuscular DiseasesStomatognathic DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

TherapeuticsElectric Stimulation TherapyPhysical Therapy ModalitiesRehabilitationAnalgesiaAnesthesia and Analgesia

Study Officials

  • Nilay Şahin, Prof. Dr.

    Balikesir University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 28, 2026

First Posted

August 4, 2026

Study Start

April 1, 2011

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

August 4, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations